Full-Time

Associate Director

Technical Product Management

Posted on 4/11/2026

Deadline 4/24/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$142.4k - $224.1k/yr

+ Annual Bonus + Long-Term Incentive

No H1B Sponsorship

North Wales, PA, USA

Hybrid

Hybrid work model: three days on-site per week; Friday remote; days may vary by site.

Category
Product (1)
Required Skills
Veeva
Python
Github Actions
Product Management
Workday HRIS
ETL
SAP Products
Salesforce
AWS
Terraform
Ansible
REST APIs
DevOps
Requirements
  • Bachelor's degree or equivalent in Computer Engineering, Computer Science, Computer Applications, or a closely related field and 8 years of experience in the position offered or related.
  • Requires 5 years of experience with all of the following: experience across software engineering lifecycle, including planning, design of ETL solutions, coding, debugging, testing, and architecture standards definition.
  • Working with distributed teams; facilitation, marketing and persuasion skills; and communicating technical concepts to non-technical stakeholders.
  • Data integration and modeling technologies, with strong proficiency in Intelligent Data Management Cloud (IDMC) and iPaaS, as well as extensive data integration experience with enterprise applications such as Workday, Salesforce, Veeva and SAP.
  • Designing, configuring, and managing data platform using DevSecOps tools such as Terraform, Github Actions, Ansible and Python, with experience in AWS architecture and its services – inclusive of EC2, EFS, FSx, Lambda, S3 and orchestration services and analytical databases.
  • Developing and delivering digital products and services leading cross-functional teams with large portion in life sciences domain.
  • Stakeholder management skills; conducting market analysis and user research.
  • Domain expertise in life sciences and pharmaceutical manufacturing.
  • Building and provisioning engineering toolsets with high autonomy, automation, and self-service level; advising clients on related solutions and services; experience with ETL technologies and Cloud Databases.
  • Designing and building self service capabilities in the integration platform, automating deployments and workspace provisioning.
Responsibilities
  • Collaborate with CTO leaders and other API and Integration leads to identify the API and integration needs across the enterprise and help solve for these needs.
  • Partner with other foundational platforms teams, enterprise architecture, networking and cloud computing and other teams to architect, design, implement digital services and products, as well as drive their adoption in (not only) divisional teams.
  • Maximize value of the product across full lifecycle (from start to decommissioning where applicable).
  • Drive optimization of TCO and ROI realization across the products and solutions.
  • Develop business case(s) and investment plans in support of investments in the product, gain investment approvals and monitor and manage spend and ROI for the investments.
  • Prioritize backlogs, roadmaps, identify and mitigate dependencies.
  • Drive execution & successful delivery towards set OKRs. Lead (manage) global vendor relationships and cross-functional global agile teams implementing platforms or solutions (no direct reports).
  • Engage with key stakeholders and API and integration area owners across the enterprise to understand the capability needs in this area, and support these needs and address them at resilient, core-service level. In collaboration with Enterprise Architecture and other teams, define API & Integration technology and governance standards relevant to the product and customize them to domains or locations where necessary.
  • Plan and execute on transitioning services and projects to products where applicable.
  • Engage with external partners and thought leaders to keep abreast of latest technology and trends in the API & Integration domain.
  • Leverage this external perspective to influence the product and services and enable innovation to support IT teams’ API and integration needs.
  • Develop and implement communications and marketing strategies to ensure awareness and education of the product.
  • Monitor and enhance adoption and usage of the product and digital services.
  • Build, grow and support the talent in the global team.
  • Up to 10% international travel required.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Winrevair delivered $525 million in Q1 2026, becoming a second growth engine.
  • Merck raised 2026 sales guidance to $65.8 billion-$67.0 billion.
  • MK-8748 and MK-3000 expand Merck's retina pipeline beyond oncology and vaccines.

What critics are saying

  • Keytruda loses exclusivity in 2028, threatening Merck's largest profit pool.
  • Gardasil sales fell 15% in Q1 2026 amid China and Japan weakness.
  • The $9.2 billion Cidara acquisition increases execution pressure before Keytruda's patent expiry.

What makes Merck unique

  • Merck combines oncology, vaccines, animal health, and cardiometabolic R&D.
  • Keytruda generated $8.4 billion in Q1 2026 sales.
  • Merck has 69,000 employees and 130 years of biopharmaceutical history.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Merck who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Company News

BJMO
May 8th, 2026
Hybrid therapy breaks through: drugs and apps used together against rare tumors.

Hybrid therapy breaks through: drugs and apps used together against rare tumors. Pharmaceuticals Remepy and Merck explore hybrid treatment approach for rare tumors, combining drugs with AI-driven digital protocols via an app to enhance effectiveness. This innovation specifically targets cancers with unmet medical needs, where behavioral support, physiotherapy, and symptom monitoring can reinforce pharmacological effects. AI-driven app The Remepy app is a personalized digital therapeutic platform delivering evidence-based interventions via a mobile application, designed to stimulate neuroplasticity, balance the immune system, and promote behavioral change. It combines multisensory stimulation (visual, auditory, and tactile) with protocols such as cognitive behavioral therapy, mindfulness, psychoeducation, sensory modulation, and physiotherapy exercises. The app simultaneously activates multiple mechanisms: it reduces systemic inflammation through stress reduction, enhances brain plasticity via enriched multisensory environments, triggers the reward system to improve therapy adherence, and improves motor control with exercises for speech, balance, and fine motor skills. For emotional and cognitive support, it provides attention training, emotion regulation, and sleep interventions - all AI-driven and personalized in real-time through patient data and smart notifications. RMPY-008 study The Remepy-conducted RMPY-008 study, a randomized controlled trial in 103 adults with subjective cognitive decline, tested the app over three weeks. The design included randomization to intervention or control, with pre- and post-measurements of inflammatory biomarkers, psychological scales, and fMRI for brain connectivity. Results showed significant reductions in pro-inflammatory cytokines (TNF-α, IL-17, IL-23, IL-12, IFN-γ, MCP-1), improved mood and resilience, and enhanced fronto-limbic connectivity, with 94% therapy adherence. Hybrid therapy collaboration The collaboration focuses on Merck's rare tumor portfolio, where hybrid therapies could reduce toxicity and improve outcomes through personalized remote care. Examples include guided physiotherapy, pain management, and medication tracking - ideal for heterogeneous diseases with high care needs. This approach leverages recent FDA frameworks for combined drug-software products, with potential for label expansions. References * Remepy press release * Catalogna, M., Saporta, N., Nathansohn-Levi, B. et al. Mobile application leads to psychological improvement and correlated neuroimmune function change in subjective cognitive decline. npj Digit. Med. 8, 359 (2025). https://doi.org/10.1038/s41746-025-01765-1

Castlefield
Apr 27th, 2026
Engagement update with Merck & co on animal testing and packaging.

Engagement update with Merck & co on animal testing and packaging. By Ffion Spencer * Share * April 27/04/2026, 12:00 AM As part of its ongoing efforts to improve performance across key environmental, social, transparency and governance (E.S.T.) metrics, Castlefield Partners Limited recently engaged with US pharmaceutical company Merck & co., held in the castlefield thoughtful World Equity Fund, to discuss its approach to animal testing, the use of animal-derived ingredients, and packaging practices. At a recent External Advisory Committee meeting, the committee highlighted increasing numbers of animals being used in animal testing across the pharmaceutical sector. Around the same time, Castlefield Partners Limited also received a client query relating to the use of animal derived ingredients in pharmaceutical products. This engagement therefore focused on three material topics for the pharmaceutical industry: animal testing, the use of animal derived ingredients in products, and plastic use. In its initial response, Merck explained that it makes extensive use of non animal research methods, including in vitro techniques, computer modelling and advanced imaging, prior to or instead of animal studies. The company shared that approximately 96% of its research animals are rodents and confirmed that it maintains detailed records on animal use across species, purpose and site, including research carried out by third party organisations on Merck's behalf. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. While this response suggests a baseline level of governance and oversight, Castlefield Partners Limited believe there is scope for further progress. Castlefield Partners Limited has followed up and are awaiting further written responses.Castlefield Partners Limited note that some peers, including French pharmaceutical company Sanofi, which is also held in the World Equity Fund, publish the total number of animals used for scientific research on an annual basis. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. On animal derived ingredients, Merck highlighted the use of specialised tools to identify potential non animal alternatives, indicating consideration of reduction and substitution where scientifically feasible. On plastics, the company shared that it has developed a long term roadmap aimed at reducing the environmental impact of its packaging, suggesting an acknowledgement of plastics as a material environmental issue within its operations. Overall, while Merck provided high level information across all three topics, the most detailed discussion related to animal testing, reflecting its materiality to the sector. Outcome: Its engagement confirmed that Merck has a level of baseline governance on these topics. However, further engagement with the company is required, particularly in relation to transparency and disclosure on the number of animals used in scientific testing. Information is accurate as at 20.04.2026. Opinions constitute the fund manager's judgement as of this date and are subject to change without warning. The officers, employees and agents of CIP may have positions in any securities mentioned herein. This material may not be distributed, published or reproduced in whole or in part. With investment, capital is at risk.

Yahoo Finance
Apr 14th, 2026
Merck keeps Keytruda cancer drug prices high as single dose reaches $163K

Merck's cancer drug Keytruda has become a pricing flashpoint in US healthcare, with a single 400mg dose billed at $162,567 at a California clinic, despite Merck's list price of $24,000. The drug generated $31.7 billion in worldwide sales in 2025, representing nearly half of Merck's revenue. A joint investigation by the International Consortium of Investigative Journalists and USA TODAY found Merck employs multiple tactics to maintain high prices, including building patent walls against generic competition, lobbying against Medicare price negotiations, and maintaining higher dosing despite studies suggesting weight-based dosing would be effective and cheaper. Whilst Merck CEO Robert Davis pledged support for President Trump's drug pricing initiatives in December, he made no commitments regarding Keytruda. Merck attributes US price inflation to pharmacy benefit managers and insurers who add fees and rebates.

Longevity.Technology
Apr 9th, 2026
Merck bets $838M on antibody startup Infinimmune for faster drug discovery

Merck has announced a collaboration with Infinimmune, a California-based biotech founded in 2022, worth up to $838 million to discover new antibody drug candidates. The deal targets multiple undisclosed targets selected by Merck, though upfront payment details were not disclosed. Infinimmune's platform identifies promising antibodies by studying memory B cells from the human immune system. The company claims it can identify antibodies binding to a target within one week and prepare candidates for animal studies in roughly three months. Chief executive Wyatt McDonnell described the approach as building a massive database of immune cell information that can be searched for matching antibodies. The 10-person startup is also developing IFX-101, its lead candidate for moderate-to-severe atopic dermatitis, designed for quarterly or twice-yearly dosing.

Yahoo Finance
Apr 7th, 2026
JPMorgan raises Merck price target to $135 as EU approves KEYTRUDA for ovarian cancer

Merck & Co. (NYSE: MRK) received a price target increase from JPMorgan to $135 from $125 on 6 April, maintaining an Overweight rating ahead of its 30 April earnings report. The firm highlighted Merck's pipeline as the primary focus, citing a favourable risk-return setup with key data readouts expected in 2026 and 2027. On 2 April, Merck announced EU approval for KEYTRUDA combined with paclitaxel for adults with platinum-resistant ovarian, fallopian tube or primary peritoneal carcinoma. The approval marks the first PD-1 inhibitor-based option for eligible patients with platinum-resistant ovarian cancer in the EU and extends across all 27 member states plus Iceland, Liechtenstein and Norway.

INACTIVE